CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (199,228)	$ (2,483)	$ 32,779
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	155,538	99,886	69,103
Impairment of intangible assets	319,246	19,663	0
Provision for bad debt expense	3,852	3,209	0
Amortization of premium/discount on purchased securities	302	624	2,152
Write-down of inventory to net realizable value	0	0	1,235
Gain (loss) on disposal of property and equipment	265	0	0
Non-cash equity-based compensation expense	23,664	22,543	17,237
Non-cash IPR&D expense	945	0	0
Non-cash loss on debt extinguishment	10,301	0	6,426
Amortization of debt discount and debt issuance costs	14,395	12,105	11,379
(Loss) gain on sale of investments, net	70	38	(14)
Change in fair value of contingent consideration	(47,686)	25,683	4,271
Deferred income taxes	(178,421)	7,279	5,007
Changes in operating assets and liabilities:
Accounts receivable, net	(14,978)	(9,906)	(36,913)
Inventories	(2,331)	(2,355)	(5,237)
Receivable from collaboration	0	428	4,090
Prepaid and other current assets	(285)	4,095	4,034
Accounts payable and accrued expenses	16,834	49,037	7,876
Deferred revenues	17,080	24,522	(22,197)
Payment of contingent consideration in excess of acquisition date fair value	(10,432)	(8,116)	0
Repayment of term loan attributable to original issue discount	0	0	(12,491)
Other assets and liabilities	(1,223)	(30)	7,244
Net cash provided by operating activities	107,908	246,222	95,981
Cash flows from investing activities:
Acquisition of Lumara Health, net of acquired cash	0	0	562
Acquisition of CBR, net	0	0	(682,356)
Proceeds from sales or maturities of investments	294,957	127,479	208,966
Purchase of investments	(127,249)	(194,723)	(424,759)
Acquisition of Intrarosa developed technology	(55,800)	0	0
Change in restricted cash	0	0	(195)
Capital expenditures	(8,988)	(5,460)	(1,259)
Net cash provided by (used in) investing activities	102,920	(72,704)	(899,041)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses	0	0	407,477
Long-term debt principal payments	(353,125)	(17,502)	(327,509)
Proceeds from long-term debt	0	0	834,750
Proceeds from 2022 Convertible Notes issuance	320,000	0	0
Payments to repurchase 2019 Convertible Notes	(191,730)	0	0
Proceeds to settle warrants	323	0	0
Payment of convertible debt issuance costs	(9,553)	0	(10,004)
Payment of contingent consideration	(39,793)	(92,130)	(456)
Payment to former CBR shareholders	0	0	(7,195)
Payments for repurchases of common stock	(19,466)	(20,000)	0
Proceeds from the issuance and exercise of common stock options	3,021	3,885	15,406
Payments of employee tax withholding related to equity-based compensation	(2,696)	(2,171)	0
Net cash (used in) provided by financing activities	(293,019)	(127,918)	912,469
Net (decrease) increase in cash and cash equivalents	(82,191)	45,600	109,409
Cash and cash equivalents at beginning of the year	274,305	228,705	119,296
Cash and cash equivalents at end of the year	192,114	274,305	228,705
Supplemental data of cash flow information:
Cash paid for taxes	5,296	5,309	2,373
Cash paid for interest	56,959	62,381	28,014
Non-cash investing activities:
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset	13,500
Endoceutics, Inc.
Non-cash investing activities:
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset	12,555	0	0
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	$ 9,300	$ 0	$ 0